Nanobiotix S.A. Logo

Nanobiotix S.A.

Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.

NBTX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering the discovery, development, and commercialization of physics-based nanotherapeutics. The company's lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed for direct injection into solid tumors. When activated by radiotherapy, NBTXR3 locally amplifies the radiation dose within the tumor, aiming to enhance cancer cell destruction without increasing exposure to surrounding healthy tissues. This process is also intended to prime the immune system to attack metastatic cancer cells. Through a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, Nanobiotix is co-developing NBTXR3, initially focusing on cancers of the head, neck, and lungs for patient populations with limited treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Nanobiotix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT
Pulmatrix, Inc. Logo
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America
PULM
PUMA BIOTECHNOLOGY, INC. Logo
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America
PBYI
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland
PUR
PureTech Health plc Logo
A clinical-stage biotherapeutics firm developing new medicines for devastating diseases.
United States of America
PRTC

Talk to a Data Expert

Have a question? We'll get back to you promptly.